SCHEMBL6538536

SCHEMBL6538536

NC(=S)NNC(=O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTDSP1 Q9GZU7 2/20 0.72
NPC1 O15118 2/20 0.72
RAB9A P51151 2/20 0.72
ALDH1A1 P00352 4/20 0.65
MAPT P10636 3/20 0.65
PDCD1 Q15116 1/20 0.59
CD274 Q9NZQ7 1/20 0.59
CA1 P00915 2/20 0.59
CA9 Q16790 2/20 0.59
SMN1; SMN2 Q16637 3/20 0.58
HPGD P15428 1/20 0.58
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
KDM4E B2RXH2 1/20 0.57
GAA P10253 1/20 0.57
AGTR1 P30556 1/20 0.57
HTT P42858 1/20 0.57
POLB P06746 1/20 0.55
DHODH Q02127 1/20 0.54
ADAMTS4 O75173 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28591667 0.95 NPC1 (0.69) CTDSP1NPC1RAB9AALDH1A1MAPT
SCHEMBL37273 0.89 ALDH1A1 (0.68) CTDSP1NPC1RAB9AALDH1A1CA1
SCHEMBL27960024 0.82 ALDH1A1 (0.59) CTDSP1NPC1RAB9AALDH1A1CA1
SCHEMBL29123185 0.81 CA1 (0.67) NPC1RAB9AALDH1A1MAPTCA1
SCHEMBL5638972 0.81 RAB9A (0.84) CTDSP1NPC1RAB9AALDH1A1MAPT
SCHEMBL3223223 0.80 HPGDS (0.54) CTDSP1NPC1RAB9AALDH1A1MAPT
SCHEMBL9257461 0.80 MAOA (0.57) CTDSP1NPC1RAB9AALDH1A1MAPT
Pyridine SCHEMBL28224544 0.79 CA1 (0.75) CTDSP1NPC1RAB9AALDH1A1CA1
SCHEMBL14527275 0.79 ALDH1A1 (1.00) CTDSP1NPC1RAB9AALDH1A1MAPT
SCHEMBL7819605 0.78 CA1 (0.62) CTDSP1NPC1RAB9AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6743776-B2 ANTIFUNGAL, BETA-1,3-GLUCAN SYNTHASE INHIBITOR, PNEUMOCYSTIS CARINII; AMIDATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-06-01 US disclosed
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY ASTELLAS PHARMA INC. (JP) 2002-12-19 US disclosed
EP-0941236-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-09-15 EP disclosed
WO-1998023637-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-06-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020193560-A1 CYCLOHEXAPEPTIDES HAVING ANTIMICROBIAL ACTIVITY NGLY1, CHIT1, MANBA CTDSP1 282/4885NPC1 1607/4885RAB9A 3674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.